Current Treatments of Hepatobiliary Cancer

Early diagnosis of rare tumors arising in silent regions is a major challenge and the principal obstacle to curative therapy. Refractoriness to currently-available therapies is the other obstacle. Both of these limitations require further research and clinical application of new findings. The general term of hepatobiliary cancers encompasses a wide range of malignancies from the very rare gall bladder and bile duct cancers to the more common--especially in Chinese patients infected with hepatitis viruses--hepatocellular cancer and its more rare variants. Gaps exist along the trajectory of these diseases, starting with early and accurate diagnosis and rational use of biomarkers through decisions about surgery and relief of symptoms (e.g. biliary obstruction, pain, ascites), to the selection and application of optimal local and systemic therapies.

EVENT DETAILS AND REGISTRATION

Date:May 04, 2017

Time: 05:30 PM - 07:30 PM (PT)

Location:City of Hope, Visitor Center, 1500 E. Duarte Rd., Duarte, CA 91010

Event Is:At the end of this continuing medical education activity, participants should be able to:

  • Identify possible opportunities for sensitive and specific methods to diagnose hepatobiliary malignancies at the surgically-resectable stage
  • Engage a multidisciplinary team to manage patients with these malignancies
  • Select based on evidence-based guidelines and emerging trial data the best available and tolerable therapy for each malignancy, by stage and by patient characteristics and comorbidities

ADDITIONAL DETAILS:

Objectives:

At the end of this continuing medical education activity, participants should be able to:
  • Identify possible opportunities for sensitive and specific methods to diagnose hepatobiliary malignancies at the surgically-resectable stage
  • Engage a multidisciplinary team to manage patients with these malignancies
  • Select based on evidence-based guidelines and emerging trial data the best available and tolerable therapy for each malignancy, by stage and by patient characteristics and comorbidities

Who should attend:

Medical Oncologists, Gastroenterologists, Hepatologists, Surgical Oncologists, Radiologists, Radiation Oncologists and other allied health care professionals who treat patients hepatobiliary malignancies

CME credits:ACCREDITATION STATEMENT: City of Hope is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. CREDIT DESIGNATION: City of Hope designates this live activity for a maximum of 1.5 AMA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. The following credit type(s) are being offered for this course: •  AMA PRA Category1™  (1.5) The following may apply AMA Category 1 Credit(s)™ for license renewal: Registered Nurses: Nurses may report up to 1.5 credit hour(s) toward the continuing education requirements for license renewal by their state Board of Registered Nurses (BRN). CME may be noted on the license renewal application in lieu of a BRN provider number. Physician Assistants: The National Commission on Certification of Physicians Assistants states that AMA Category 1 Credit(s)™ accreditedTM

R.S.V.P.: https://cme.cityofhope.org/register.html?pid=8016

Web Link:https://cme.cityofhope.org/register.html?pid=8016

Contact:

Contact Us: [email protected] or 626-218-5622